Olga Solovyeva

Olga Solovyeva

Auto-generated profile, based on publicly available information

Olga Solovyeva

Institute of Cancer Research, London SM2 5NG, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2023 in BMJ
Verified
Journal Article
Open access
PDF file
CYChristina Yap
Christina Yap
OSOlga Solovyeva
Olga Solovyeva
JBJohann de Bono
Johann de Bono
JRJan Rekowski
Jan Rekowski
DPDhrusti Patel
Dhrusti Patel
CWChristopher J Weir
Christopher J Weir
The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new items and 19 modified items) to early phase dose-finding trials with interim dose escalation or de-escalation strategies. Such trials generally focus on safety, tolerability, activity, and recommending dosing and scheduling regimens for further clinical development. These trials are often inadequately reported, hampering their informativeness and making evidence informed decisions difficult. The CONSORT-DEFINE guidance aims to develop an international, consensus driven guideline for reporting early phase dose-finding trials to promote transparency, completeness, reproducibility, and facilitate the interpretation of the results. The CONSORT-DEFINE guidance provides recommendations for essential items that should be reported in early phase dose-finding trials to promote greater clarity, reproducibility, informativeness, and usefulness of results.

20 October 2023 in BMJ
Verified
Journal Article
Open access
PDF file
CYChristina Yap
Christina Yap
JRJan Rekowski
Jan Rekowski
MUMoreno Ursino
Moreno Ursino
OSOlga Solovyeva
Olga Solovyeva
DPDhrusti Patel
Dhrusti Patel
JBJohann de Bono
Johann de Bono
SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 provides guidance for clinical trial protocol writing. However, neither the original guidance nor its extensions adequately cover the features of early phase dose-finding trials. The SPIRIT Dose-finding Extension (DEFINE) statement is a new guideline that provides recommendations for essential items that should be provided in the protocols of these trials. It details extensions to the SPIRIT 2013 guidance, incorporating 17 new items and modifying 15 existing items. The purpose of this guideline is to promote transparency, completeness, reproducibility of methods, and interpretation of early phase dose-finding trial protocols. It is envisioned that the resulting improvements in the design and conduct of early phase clinical trials will ultimately reduce research inefficiencies and inconsistencies, driving transformational advances in clinical care.

6 January 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CYChristina Yap
Christina Yap
ABAlun Bedding
Alun Bedding
JBJohann de Bono
Johann de Bono
MDMunyaradzi Dimairo
Munyaradzi Dimairo
AEAude Espinasse
Aude Espinasse
CWChristopher J. Weir
Christopher J. Weir

5 July 2023 in BMC Medicine
Verified
Journal Article
Open access
PDF file
OSOlga Solovyeva
Olga Solovyeva
MDMunyaradzi Dimairo
Munyaradzi Dimairo
CWChristopher J. Weir
Christopher J. Weir
SHSiew Wan Hee
Siew Wan Hee
AEAude Espinasse
Aude Espinasse
CYChristina Yap
Christina Yap
Background: Early phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials. Guidance exists for clinical trial protocols and completed trial reports in the SPIRIT and CONSORT guidelines, respectively. However, both guidelines and their extensions do not adequately address the characteristics of EPDF trials. Building on the SPIRIT and CONSORT checklists, the DEFINE study aims to develop international consensus-driven guidelines for EPDF trial protocols (SPIRIT-DEFINE) and reports (CONSORT-DEFINE).Methods: The initial generation of candidate items was informed by reviewing published EPDF trial reports. The early draft items were refined further through a review of the published and grey literature, analysis of real-world examples, citation and reference searches, and expert recommendations, followed by a two-round modified Delphi process. Patient and public involvement and engagement (PPIE) was pursued concurrently with the quantitative and thematic analysis of Delphi participants’ feedback.Results: The Delphi survey included 79 new or modified SPIRIT-DEFINE (n = 36) and CONSORT-DEFINE (n = 43) extension candidate items. In Round One, 206 interdisciplinary stakeholders from 24 countries voted and 151 stakeholders voted in Round Two. Following Round One feedback, one item for CONSORT-DEFINE was added in Round Two. Of the 80 items, 60 met the threshold for inclusion (≥ 70% of respondents voted critical: 26 SPIRIT-DEFINE, 34 CONSORT-DEFINE), with the remaining 20 items to be further discussed at the consensus meeting. The parallel PPIE work resulted in the development of an EPDF lay summary toolkit consisting of a template with guidance notes and an exemplar.Conclusions: By detailing the development journey of the DEFINE study and the decisions undertaken, we envision that this will enhance understanding and help researchers in the development of future guidelines. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines will allow investigators to effectively address essential items that should be present in EPDF trial protocols and reports, thereby promoting transparency, comprehensiveness, and reproducibility.Trial registration: SPIRIT-DEFINE and CONSORT-DEFINE are registered with the EQUATOR Network (https://www.equator-network.org/).

10 March 2026 in Journal of Clinical Oncology
Verified
Journal Article
Open access
EAEmily Alger
Emily Alger
OAOlalekan Lee Aiyegbusi
Olalekan Lee Aiyegbusi
ADAmylou Dueck
Amylou Dueck
AMAnna R. Minchom
Anna R. Minchom
MPMadeline Pe
Madeline Pe
CYChristina Yap
Christina Yap
PURPOSE: There is growing scientific interest in incorporating patient-reported outcomes (PROs) in early phase dose-finding oncology trials (DFOTs) to assess tolerability, inform dose selection, and guide later stage trial design. However, research indicates that PRO objectives in DFOTs are often unclear. The Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Research Objectives Recommendations (OPTIMISE-ROR) project was established to support trialists to effectively incorporate PROs into DFOTs. METHODS: Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework, guideline development included the following: (1) a methodological review of published DFOTs incorporating PROs; (2) candidate item generation, refined through expert consultation; (3) a two-round international multistakeholder Delphi survey (N = 109 in Round 1 [October 2024]; N = 96 in Round 2 [December 2024]); and (4) an independently chaired virtual consensus meeting (N = 31; January 2025) where multidisciplinary, international experts reviewed and voted to finalize items for inclusion. RESULTS: Consensus was reached on six recommendations emphasizing three core PRO tolerability concepts: overall side effect impact, symptomatic adverse events, and overall health-related quality of life. The integration of PROs to inform final dose recommendations in dose escalation and optimization trials should be considered, regardless of trial design. The recommendations highlight the importance of PRO data analysis over time and across dose levels, defining PRO research objectives as descriptive or statistically powered, and assessing PRO-related end points to guide end point selection for subsequent studies. CONCLUSION: This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and regulatory evaluation—ultimately contributing to the development of safer, more effective therapies.

3 June 2025 in Life
Verified
Journal Article
Open access
PDF file
OAOleksii Avdieiev
Oleksii Avdieiev
Sergey DenisovSergey Denisov
Sergey Denisov
AAAsh Ajeer
Ash Ajeer
LALois Adams
Lois Adams
CGCharlene Greenwood
Charlene Greenwood
PLPavel Lazarev
Pavel Lazarev
Structural biomarkers determined by X-ray scattering of the tissues can complement conventional diagnostics and provide a pathway for early detection of diseases. In the present study, mouse models were utilized to observe the progression of prostate cancer. We induced cancer in the left lobe of the mouse prostate, whilst the right lobe was left uninoculated. The mice were sacrificed at increasing systematic time points, and lobe samples were subsequently analyzed using X-ray scattering. Control samples were also collected from healthy mice sacrificed at the same time points. This investigation revealed that the ratio between the X-ray scattering peaks associated with the lipids and water can serve as a structural biomarker of cancer, and this biomarker develops as the tumor advances. The obtained cancer trajectory can serve as a baseline for the determination of the disease stage, and the biomarker movement along the trajectory can be evidence of the healing or disease progression.